{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:15:38Z","timestamp":1769840138911,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Recently, docetaxel treatment of metastatic prostate cancer patients shifted towards the hormone-sensitive stage of the disease. There are contradictive reports on differences in toxicity of docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) patients. Possible differences in toxicity might be attributed to different pharmacokinetics (PK) in the two patient populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with mCRPC or mHSPC and a standard indication for docetaxel treatment were included in the study. All patients had suppressed serum testosterone levels (\u2264\u20090.5\u00a0ng\/mL or 1.73\u00a0nmol\/L). Venous blood samples were obtained at the first docetaxel treatment, until 48\u00a0h after infusion. Plasma concentrations of docetaxel, unbound docetaxel and docetaxel metabolites were measured using validated liquid chromatography coupled tandem mass spectrometry (LC\u2013MS\/MS) assays and compared between the two groups. Moreover, serum levels of docetaxel transporting \u03b11-acid glycoprotein were measured and docetaxel toxicity recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of ten mCRPC and nine mHSPC patients were included in the study. The two cohorts differed in the number of prior treatments and opiate use, which were higher for mCRPC patients. The docetaxel PK was not different between mCRPC and mHSPC patients, with areas under the plasma concentration versus time curve (AUC<jats:sub>0-48<\/jats:sub>) 1710 [coefficient of variation (CV) 28.4%] and 1486 (CV 25.2%) ng\/mL*h (<jats:italic>p<\/jats:italic>\u2009=\u20090.27), respectively. Also, the PK profile of unbound docetaxel, M1\/M3, M2 and M4 metabolites were similar in both groups. Docetaxel doses were reduced in 50% of the mCRPC patients and 11% of the mHSPC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The PK profile of docetaxel was similar in mCPRC and mHSPC patients. Therefore, possible differences in toxicity between mCRPC and mHSPC patients cannot be explained by differences in docetaxel PK in our study population. These results suggest that treatment adaptations are not recommended in the new population of patients with mHSPC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-022-04433-3","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T10:03:56Z","timestamp":1650881036000},"page":"785-793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2674-1291","authenticated-orcid":false,"given":"Marit A. C.","family":"Vermunt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merel","family":"van Nuland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa T.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos. H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andries M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"issue":"15","key":"4433_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502\u20131512. https:\/\/doi.org\/10.1056\/NEJMoa040720","journal-title":"N Engl J Med"},{"issue":"8","key":"4433_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"issue":"2","key":"4433_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D et al (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17(2):243\u2013256. https:\/\/doi.org\/10.1016\/S1470-2045(15)00489-1","journal-title":"Lancet Oncol"},{"key":"4433_CR4","doi-asserted-by":"publisher","first-page":"CD012816","DOI":"10.1002\/14651858.cd01281","volume":"10","author":"NJ Sathianathen","year":"2018","unstructured":"Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD et al (2018) Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst Rev 10:CD012816. https:\/\/doi.org\/10.1002\/14651858.cd01281","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4433_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149\u2013158. https:\/\/doi.org\/10.1016\/S1470-2045(12)70560-0","journal-title":"Lancet Oncol"},{"issue":"2","key":"4433_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12032-018-1238-9","volume":"36","author":"I Kushnir","year":"2019","unstructured":"Kushnir I, Koczka K, Ong M, Canil C, Bosse D, Sabri E et al (2019) The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity. Med Oncol 36(2):18. https:\/\/doi.org\/10.1007\/s12032-018-1238-9","journal-title":"Med Oncol"},{"issue":"9","key":"4433_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.clon.2016.03.006","volume":"28","author":"JS Tanguay","year":"2016","unstructured":"Tanguay JS, Catlow C, Smith C, Barber J, Staffurth J, Kumar S et al (2016) High risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront docetaxel chemotherapy in usual clinical practice. Clin Oncol (R Coll Radiol) 28(9):611. https:\/\/doi.org\/10.1016\/j.clon.2016.03.006","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"10","key":"4433_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.clon.2016.07.004","volume":"28","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Ritchie AW, Parmar MK (2016) Response to \u201chigh risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront docetaxel chemotherapy in usual clinical practice\u201d, by Tanguay et al. Clin Oncol (R Coll Radiol) 28(10):666\u20137. https:\/\/doi.org\/10.1016\/j.clon.2016.07.004","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"4433_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/bju.14025","volume":"121","author":"RJ Rulach","year":"2018","unstructured":"Rulach RJ, McKay S, Neilson S, White L, Wallace J, Carruthers R et al (2018) Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU Int 121(2):268\u2013274. https:\/\/doi.org\/10.1111\/bju.14025","journal-title":"BJU Int"},{"issue":"7","key":"4433_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12032-016-0793-1","volume":"33","author":"MT Schweizer","year":"2016","unstructured":"Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY et al (2016) Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. Med Oncol 33(7):77. https:\/\/doi.org\/10.1007\/s12032-016-0793-1","journal-title":"Med Oncol"},{"issue":"12","key":"4433_CR11","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.urolonc.2019.07.005","volume":"37","author":"R Mager","year":"2019","unstructured":"Mager R, Savko O, Bohm K, Thomas A, Dotzauer R, Borgmann H et al (2019) Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. Urol Oncol 37(12):999\u20131005. https:\/\/doi.org\/10.1016\/j.urolonc.2019.07.005","journal-title":"Urol Oncol"},{"issue":"7","key":"4433_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ctrv.2015.04.012","volume":"41","author":"AJ Nieuweboer","year":"2015","unstructured":"Nieuweboer AJ, de Morree ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH (2015) Inter-patient variability in docetaxel pharmacokinetics: a review. Cancer Treat Rev 41(7):605\u2013613. https:\/\/doi.org\/10.1016\/j.ctrv.2015.04.012","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"4433_CR13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/cam4.2003","volume":"8","author":"AHM de Vries Schultink","year":"2019","unstructured":"de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM et al (2019) Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: a meta-analysis and evaluation of a clinical cohort. Cancer Med 8(4):1406\u20131415. https:\/\/doi.org\/10.1002\/cam4.2003","journal-title":"Cancer Med"},{"issue":"30","key":"4433_CR14","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","volume":"28","author":"RM Franke","year":"2010","unstructured":"Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A (2010) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28(30):4562\u20134567. https:\/\/doi.org\/10.1200\/JCO.2010.30.7025","journal-title":"J Clin Oncol"},{"issue":"6","key":"4433_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00280-021-04259-5","volume":"87","author":"MAC Vermunt","year":"2021","unstructured":"Vermunt MAC, van der Heijden LT, Hendrikx JJMA, Schinkel AH, de Weger VA, van der Putten E et al (2021) Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006\/r in patients with prostate cancer versus patients with other advanced solid tumours. Cancer Chemother Pharmacol 87(6):855\u2013869. https:\/\/doi.org\/10.1007\/s00280-021-04259-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4433_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clpt.2004.09.005","volume":"77","author":"SD Baker","year":"2005","unstructured":"Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J et al (2005) Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 77(1):43\u201353","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"4433_CR17","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/rcm.6654","volume":"27","author":"JJMA Hendrikx","year":"2013","unstructured":"Hendrikx JJMA, Dubbelman AC, Rosing H, Schinkel AH, Schellens JHM, Beijnen JH (2013) Quantification of docetaxel and its metabolites in human plasma by liquid chromatography\/tandem mass spectrometry. Rapid Commun Mass Spectrom 27(17):1925\u20131934. https:\/\/doi.org\/10.1002\/rcm.6654","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"28","key":"4433_CR18","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1016\/j.jchromb.2011.08.034","volume":"879","author":"JJ Hendrikx","year":"2011","unstructured":"Hendrikx JJ, Hillebrand MJ, Thijssen B, Rosing H, Schinkel AH, Schellens JH et al (2011) A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879(28):2984\u20132990. https:\/\/doi.org\/10.1016\/j.jchromb.2011.08.034","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"12","key":"4433_CR19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34(12):1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"4433_CR20","unstructured":"R-development Core Team (2009) R: a language and environment for statistical computing. https\/www.r-project.org"},{"issue":"5","key":"4433_CR21","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/bcp.13889","volume":"85","author":"BPS Belderbos","year":"2019","unstructured":"Belderbos BPS, Hussaarts K, van Harten LJ, Oomen-de Hoop E, de Bruijn P, Hamberg P et al (2019) Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: a randomized drug-drug interaction study. Br J Clin Pharmacol 85(5):986\u2013992. https:\/\/doi.org\/10.1111\/bcp.13889","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4433_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","volume":"16","author":"R Bruno","year":"1998","unstructured":"Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinink WW, van Oosterom AT et al (1998) Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187\u2013196. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.187","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04433-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T09:03:40Z","timestamp":1653555820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04433-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4433"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04433-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest or competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Medical Ethical Committee of the Netherlands Cancer Institute. The study was performed in line with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent before start of any study procedures according to Good Clinical Practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Since all data are anonymized before publication, no additional consents are needed for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}